Skip to content
CSU Mini Series 2025_Registration Site_banner 1920x400_v2_41825_RGB
8 events found.

Events Search and Views Navigation

Event Views Navigation

  • List
  • Month
  • Summary

Filters

Changing any of the form inputs will cause the list of events to refresh with the filtered results.

Allergist Led Programs

Dermatologist Led Programs

Today

June 2025

Mon 16
June 16 @ 12:15 pm - 1:15 pm EDT

Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Skin Diseases Driven in Part by Type 2 Inflammation
by Andrew Mastro, PA-C

Virtual (Zoom)

Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin…

Tue 17
June 17 @ 12:15 pm - 1:15 pm CDT

Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Melissa Costner, MD

Virtual (Zoom)

Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate CSU patients 12+ years…

Tue 17
June 17 @ 12:15 pm - 1:15 pm MDT

The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients
by Adam Friedman, MD

Virtual (Zoom)

Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU); which cytokines play key roles in…

Wed 18
June 18 @ 12:15 pm - 1:15 pm PDT

Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Skin Diseases Driven in Part by Type 2 Inflammation
by Lakshi Aldredge, NP

Virtual (Zoom)

Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin…

Mon 23
June 23 @ 12:15 pm - 1:15 pm MDT Event Series Allergist-led programs

A Treatment Option for Appropriate Patients with Skin Diseases Driven in Part by Type 2 Inflammation
by Dareen Siri, MD

Virtual (Zoom)

Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation.

Tue 24
June 24 @ 12:15 pm - 1:15 pm EDT Event Series Allergist-led programs

A Treatment Option for Appropriate Patients with Skin Diseases Driven in Part by Type 2 Inflammation
by Kathryn Sowerwine, MD

Virtual (Zoom)

Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation.

Wed 25
June 25 @ 12:15 pm - 1:15 pm CDT Event Series Allergist-led programs

A Treatment Option for Appropriate Patients with Skin Diseases Driven in Part by Type 2 Inflammation
by Dareen Siri, MD

Virtual (Zoom)

Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation.

Thu 26
June 26 @ 12:15 pm - 1:15 pm PDT Event Series Allergist-led programs

A Treatment Option for Appropriate Patients with Skin Diseases Driven in Part by Type 2 Inflammation
by Raffi Tachdjian, MD

Virtual (Zoom)

Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation.

  • Previous Events
  • Today
  • Google Calendar
  • iCalendar
  • Outlook 365
  • Outlook Live
  • Export .ics file
  • Export Outlook .ics file

INDICATIONS

Atopic Dermatitis: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Prurigo Nodularis: DUPIXENT is indicated for the treatment of adult patients with prurigo nodularis (PN).

Chronic Spontaneous Urticaria: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Limitations of Use: DUPIXENT is not indicated for treatment of other forms of urticaria.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT versus placebo. Conjunctivitis was the most frequently reported eye disorder. Most AD subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis occurred more frequently in prurigo nodularis subjects who received DUPIXENT versus placebo; these subjects recovered or were recovering during the treatment period. There were no cases of keratitis reported in the PN development program. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in AD patients. Some patients reported visual disturbances (e.g., blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new-onset or worsening eye symptoms. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Psoriasis: Cases of new-onset psoriasis have been reported with the use of DUPIXENT for the treatment of atopic dermatitis, including in patients without a family history of psoriasis. In postmarketing reports, these cases resulted in partial or complete resolution of psoriasis with discontinuation of dupilumab, with or without use of supplemental treatment for psoriasis (topical or systemic). Those who continued dupilumab received supplemental treatment for psoriasis to improve associated symptoms. Advise patients to report new-onset psoriasis symptoms. If symptoms persist or worsen, consider dermatologic evaluation and/or discontinuation of DUPIXENT.

 

Arthralgia and Psoriatic Arthritis: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Cases of new-onset psoriatic arthritis requiring systemic treatment have been reported with the use of DUPIXENT. Advise patients to report new-onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.

ADVERSE REACTIONS:

Most common adverse reactions are:

  • Atopic Dermatitis (incidence ≥1%): injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with AD. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with AD, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.
  • Prurigo Nodularis (incidence ≥2%): nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.
  • Chronic Spontaneous Urticaria (incidence ≥2%): injection site reactions.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information

San Reg Pair 2022

©2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

DUPIXENT® is a registered trademark of Sanofi Biotechnology.

                     US.DUP.25.02.0196